{"success":true,"data":{"pressRelease":{"id":"133925","rtpr_id":"nNFC40cCYC","ticker":"COCH","exchange":"NASDAQ","all_tickers":["COCH"],"title":"Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th","author":"Newsfile Corp","published_at":"2026-09-02T12:30:14.807Z","article_body":"White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy\nMedical(®) Inc. (NASDAQ: COCH) (\"Envoy Medical\"), a hearing health company\nfocused on developing innovative, fully implanted hearing solutions, today\nannounced that Brent Lucas, Envoy Medical's Chief Executive Officer, will\npresent at the H.C. Wainwright 28th Annual Global Investment Conference, on\nSeptember 14-16, 2026 at the Lotte New York Palace Hotel in New York City.\n\nH.C. Wainwright Conference Presentation Details:\nPresentation Date: Tuesday, September 15, 2026\nPresentation Time: 2:00 PM ET\nLocation: Kennedy II Room, Lotte New York Palace Hotel, New York, NY\nWebcast Link: https://ir.envoymedical.com/news-events/ir-calendar\n\nTo schedule a one-on-one investor meeting with Envoy's management team, please\ncontact KCSA Strategic Communications at Envoy@kcsa.com.\n\nMr. Lucas' presentation will be made available on demand for 90 days following\nthe conference in the Investor Relations section of Envoy Medical's website at\nhttps://ir.envoymedical.com/news-events/ir-calendar.\n\nFor more information about Envoy Medical's innovation pipeline and\nintellectual property portfolio, visit www.envoymedical.com.\n\nTo be added to the Envoy Medical email distribution list, please email\nEnvoy@kcsa.com with COCH in the subject line.\n\nAbout Envoy Medical, Inc.\nEnvoy Medical (NASDAQ: COCH) is a hearing health company focused on providing\ninnovative technologies across the hearing loss spectrum. Envoy Medical has\npioneered one-of-a-kind, fully implanted devices for hearing loss, including\nits fully implanted Esteem® active middle ear implant, commercially available\nin the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an\ninvestigational device. Envoy Medical is dedicated to pushing hearing\ntechnology beyond the status quo to improve access, usability, compliance, and\nultimately quality of life.\n\nAbout the Fully Implanted Acclaim® Cochlear Implant\nWe believe the fully implanted Acclaim Cochlear Implant (\"Acclaim CI\") is a\nfirst-of-its-kind hearing device. Envoy Medical's fully implanted technology\nincludes a sensor designed to leverage the natural anatomy of the ear instead\nof a microphone to capture sound. The Acclaim CI is designed to address severe\nto profound sensorineural hearing loss that is not adequately addressed by\nhearing aids. The Acclaim CI is expected to be indicated for adults who have\nbeen deemed adequate candidates by a qualified physician.\n\nThe Acclaim Cochlear Implant received the Breakthrough Device Designation from\nthe U.S. Food and Drug Administration (FDA) in 2019.\n\nCAUTION The fully implanted Acclaim Cochlear Implant is an investigational\ndevice. Limited by Federal (or United States) law to investigational use.\n\nAbout the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)\nThe Esteem fully implanted active middle ear implant (FI-AMEI) is the only\nFDA-approved, fully implanted* hearing device for adults diagnosed with\nmoderate to severe sensorineural hearing loss allowing for 24/7 hearing\ncapability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant\nis invisible and requires no externally worn components and nothing is placed\nin the ear canal for it to function. Unlike hearing aids, you never put it on\nor take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI\nhearing implant offers true 24/7 hearing.\n\n*Once activated, the external Esteem FI-AMEI Personal Programmer is not\nrequired for daily use.\n\nImportant safety information for the Esteem FI-AMEI can be found at:\nhttps://www.envoymedical.com/safety-information.\n\nAdditional Information and Where to Find It\nCopies of the documents filed by Envoy Medical with the SEC may be obtained\nfree of charge at the SEC's website at www.sec.gov.\n\nForward-Looking Statements\nThis press release includes \"forward-looking statements\" within the meaning of\nthe \"safe harbor\" provisions of the United States Private Securities\nLitigation Reform Act of 1995. Forward-looking statements may be identified by\nthe use of words such as \"estimate,\" \"plan,\" \"project,\" \"forecast,\" \"intend,\"\n\"will,\" \"expect,\" \"anticipate,\" \"believe,\" \"seek,\" \"target\" or other similar\nexpressions that predict or indicate future events or trends or that are not\nstatements of historical matters, but the absence of these words does not mean\nthat a statement is not forward-looking. Such statements may include, but are\nnot limited to, statements regarding the expectations of Envoy Medical\nconcerning the outlook for its business, productivity, plans and goals for\nfuture operational improvements and capital investments; the ability to obtain\nadditional patents and develop future products or product improvements; the\nAcclaim CI being the first to market fully implanted cochlear implant; the\ntiming, content, and results of the Company's modular PMA submissions to the\nFDA, including the number and timing of modules and the timing of any approval\ndecision; the timing and results of approvals, site documents, logistics,\nactivations, enrollments, follow-up visits, data, and clinical trials of the\nAcclaim CI, including data from Stage 2 (which may differ from Stage 1); the\nresults of the safety and efficacy data from Stage 2 participants and the\neffect on its pooling with Stage 1 data; performance of the Acclaim CI during\nclinical trials, including improvement of patient outcomes over time after\nimplant; and the participation or any changes in participation of any\nsubjects, institutions, or healthcare professionals in such trials; the\nsafety, performance, and market acceptance of the Acclaim CI; changes in\nreimbursement for the Esteem FI-AMEI device or other changes in reimbursement\npolicies or coverage decisions, changes in the hearing health market, and\nfurther development of the Esteem FI-AMEI device; the sufficiency of the\nCompany's capital resources; the size of Envoy Medical's addressable market,\noperational performance, future market conditions or economic performance and\ndevelopments in the capital and credit markets and any information concerning\npossible or assumed future operations of Envoy Medical. The forward-looking\nstatements contained in this press release reflect Envoy Medical's current\nviews about future events and are subject to numerous known and unknown risks,\nuncertainties, assumptions and changes in circumstances that may cause its\nactual results to differ significantly from those expressed in any\nforward-looking statement. Envoy Medical does not guarantee that the events\ndescribed will happen as described (or that they will happen at all). These\nforward-looking statements are subject to a number of risks and uncertainties,\nincluding, but not limited to, changes in the market price of shares of Envoy\nMedical's Class A Common Stock; changes in or removal of Envoy Medical's\nshares inclusion in any index; Envoy Medical's success in retaining or\nrecruiting, or changes required in, its officers, key employees or directors;\nunpredictability in the medical device industry, the regulatory process to\napprove medical devices, and the clinical development process of Envoy Medical\nproducts; competition in the medical device industry, and the failure to\nintroduce new products and services in a timely manner or at competitive\nprices to compete successfully against competitors; disruptions in\nrelationships with Envoy Medical's suppliers, or disruptions in Envoy\nMedical's own production capabilities for some of the key components and\nmaterials of its products; changes in the need for capital and the\navailability of financing and capital to fund these needs; changes in interest\nrates or rates of inflation; legal, regulatory and other proceedings could be\ncostly and time-consuming to defend; changes in applicable laws or\nregulations, or the application thereof on Envoy Medical; a loss of any of\nEnvoy Medical's key intellectual property rights or failure to adequately\nprotect intellectual property rights; the effects of catastrophic events,\nincluding war, terrorism and other international conflicts; and other risks\nand uncertainties set forth in the section entitled \"Risk Factors\" and\n\"Cautionary Note Regarding Forward-Looking Statements\" in the Annual Report on\nForm 10-K filed by Envoy Medical on March 23, 2026, and in other reports Envoy\nMedical files with the SEC. If any of these risks materialize or Envoy\nMedical's assumptions prove incorrect, actual results could differ materially\nfrom the results implied by these forward-looking statements. While\nforward-looking statements reflect Envoy Medical's good faith beliefs, they\nare not guarantees of future performance. Envoy Medical disclaims any\nobligation to publicly update or revise any forward-looking statement to\nreflect changes in underlying assumptions or factors, new information, data or\nmethods, future events or other changes after the date of this press release,\nexcept as required by applicable law. You should not place undue reliance on\nany forward-looking statements, which are based only on information currently\navailable to Envoy Medical.\n\nInvestor Contact:\nPhil Carlson, Managing Director\nKCSA Strategic Communications\nO: 212.896.1233\nE: Envoy@kcsa.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/312455","article_body_html":"","raw_payload":{"data":{"id":"nNFC40cCYC","title":"Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th","author":"Newsfile Corp","ticker":"COCH","created":"2026-09-02T12:30:14.807Z","tickers":["COCH"],"exchange":"NASDAQ","article_body":"White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy\nMedical(®) Inc. (NASDAQ: COCH) (\"Envoy Medical\"), a hearing health company\nfocused on developing innovative, fully implanted hearing solutions, today\nannounced that Brent Lucas, Envoy Medical's Chief Executive Officer, will\npresent at the H.C. Wainwright 28th Annual Global Investment Conference, on\nSeptember 14-16, 2026 at the Lotte New York Palace Hotel in New York City.\n\nH.C. Wainwright Conference Presentation Details:\nPresentation Date: Tuesday, September 15, 2026\nPresentation Time: 2:00 PM ET\nLocation: Kennedy II Room, Lotte New York Palace Hotel, New York, NY\nWebcast Link: https://ir.envoymedical.com/news-events/ir-calendar\n\nTo schedule a one-on-one investor meeting with Envoy's management team, please\ncontact KCSA Strategic Communications at Envoy@kcsa.com.\n\nMr. Lucas' presentation will be made available on demand for 90 days following\nthe conference in the Investor Relations section of Envoy Medical's website at\nhttps://ir.envoymedical.com/news-events/ir-calendar.\n\nFor more information about Envoy Medical's innovation pipeline and\nintellectual property portfolio, visit www.envoymedical.com.\n\nTo be added to the Envoy Medical email distribution list, please email\nEnvoy@kcsa.com with COCH in the subject line.\n\nAbout Envoy Medical, Inc.\nEnvoy Medical (NASDAQ: COCH) is a hearing health company focused on providing\ninnovative technologies across the hearing loss spectrum. Envoy Medical has\npioneered one-of-a-kind, fully implanted devices for hearing loss, including\nits fully implanted Esteem® active middle ear implant, commercially available\nin the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an\ninvestigational device. Envoy Medical is dedicated to pushing hearing\ntechnology beyond the status quo to improve access, usability, compliance, and\nultimately quality of life.\n\nAbout the Fully Implanted Acclaim® Cochlear Implant\nWe believe the fully implanted Acclaim Cochlear Implant (\"Acclaim CI\") is a\nfirst-of-its-kind hearing device. Envoy Medical's fully implanted technology\nincludes a sensor designed to leverage the natural anatomy of the ear instead\nof a microphone to capture sound. The Acclaim CI is designed to address severe\nto profound sensorineural hearing loss that is not adequately addressed by\nhearing aids. The Acclaim CI is expected to be indicated for adults who have\nbeen deemed adequate candidates by a qualified physician.\n\nThe Acclaim Cochlear Implant received the Breakthrough Device Designation from\nthe U.S. Food and Drug Administration (FDA) in 2019.\n\nCAUTION The fully implanted Acclaim Cochlear Implant is an investigational\ndevice. Limited by Federal (or United States) law to investigational use.\n\nAbout the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)\nThe Esteem fully implanted active middle ear implant (FI-AMEI) is the only\nFDA-approved, fully implanted* hearing device for adults diagnosed with\nmoderate to severe sensorineural hearing loss allowing for 24/7 hearing\ncapability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant\nis invisible and requires no externally worn components and nothing is placed\nin the ear canal for it to function. Unlike hearing aids, you never put it on\nor take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI\nhearing implant offers true 24/7 hearing.\n\n*Once activated, the external Esteem FI-AMEI Personal Programmer is not\nrequired for daily use.\n\nImportant safety information for the Esteem FI-AMEI can be found at:\nhttps://www.envoymedical.com/safety-information.\n\nAdditional Information and Where to Find It\nCopies of the documents filed by Envoy Medical with the SEC may be obtained\nfree of charge at the SEC's website at www.sec.gov.\n\nForward-Looking Statements\nThis press release includes \"forward-looking statements\" within the meaning of\nthe \"safe harbor\" provisions of the United States Private Securities\nLitigation Reform Act of 1995. Forward-looking statements may be identified by\nthe use of words such as \"estimate,\" \"plan,\" \"project,\" \"forecast,\" \"intend,\"\n\"will,\" \"expect,\" \"anticipate,\" \"believe,\" \"seek,\" \"target\" or other similar\nexpressions that predict or indicate future events or trends or that are not\nstatements of historical matters, but the absence of these words does not mean\nthat a statement is not forward-looking. Such statements may include, but are\nnot limited to, statements regarding the expectations of Envoy Medical\nconcerning the outlook for its business, productivity, plans and goals for\nfuture operational improvements and capital investments; the ability to obtain\nadditional patents and develop future products or product improvements; the\nAcclaim CI being the first to market fully implanted cochlear implant; the\ntiming, content, and results of the Company's modular PMA submissions to the\nFDA, including the number and timing of modules and the timing of any approval\ndecision; the timing and results of approvals, site documents, logistics,\nactivations, enrollments, follow-up visits, data, and clinical trials of the\nAcclaim CI, including data from Stage 2 (which may differ from Stage 1); the\nresults of the safety and efficacy data from Stage 2 participants and the\neffect on its pooling with Stage 1 data; performance of the Acclaim CI during\nclinical trials, including improvement of patient outcomes over time after\nimplant; and the participation or any changes in participation of any\nsubjects, institutions, or healthcare professionals in such trials; the\nsafety, performance, and market acceptance of the Acclaim CI; changes in\nreimbursement for the Esteem FI-AMEI device or other changes in reimbursement\npolicies or coverage decisions, changes in the hearing health market, and\nfurther development of the Esteem FI-AMEI device; the sufficiency of the\nCompany's capital resources; the size of Envoy Medical's addressable market,\noperational performance, future market conditions or economic performance and\ndevelopments in the capital and credit markets and any information concerning\npossible or assumed future operations of Envoy Medical. The forward-looking\nstatements contained in this press release reflect Envoy Medical's current\nviews about future events and are subject to numerous known and unknown risks,\nuncertainties, assumptions and changes in circumstances that may cause its\nactual results to differ significantly from those expressed in any\nforward-looking statement. Envoy Medical does not guarantee that the events\ndescribed will happen as described (or that they will happen at all). These\nforward-looking statements are subject to a number of risks and uncertainties,\nincluding, but not limited to, changes in the market price of shares of Envoy\nMedical's Class A Common Stock; changes in or removal of Envoy Medical's\nshares inclusion in any index; Envoy Medical's success in retaining or\nrecruiting, or changes required in, its officers, key employees or directors;\nunpredictability in the medical device industry, the regulatory process to\napprove medical devices, and the clinical development process of Envoy Medical\nproducts; competition in the medical device industry, and the failure to\nintroduce new products and services in a timely manner or at competitive\nprices to compete successfully against competitors; disruptions in\nrelationships with Envoy Medical's suppliers, or disruptions in Envoy\nMedical's own production capabilities for some of the key components and\nmaterials of its products; changes in the need for capital and the\navailability of financing and capital to fund these needs; changes in interest\nrates or rates of inflation; legal, regulatory and other proceedings could be\ncostly and time-consuming to defend; changes in applicable laws or\nregulations, or the application thereof on Envoy Medical; a loss of any of\nEnvoy Medical's key intellectual property rights or failure to adequately\nprotect intellectual property rights; the effects of catastrophic events,\nincluding war, terrorism and other international conflicts; and other risks\nand uncertainties set forth in the section entitled \"Risk Factors\" and\n\"Cautionary Note Regarding Forward-Looking Statements\" in the Annual Report on\nForm 10-K filed by Envoy Medical on March 23, 2026, and in other reports Envoy\nMedical files with the SEC. If any of these risks materialize or Envoy\nMedical's assumptions prove incorrect, actual results could differ materially\nfrom the results implied by these forward-looking statements. While\nforward-looking statements reflect Envoy Medical's good faith beliefs, they\nare not guarantees of future performance. Envoy Medical disclaims any\nobligation to publicly update or revise any forward-looking statement to\nreflect changes in underlying assumptions or factors, new information, data or\nmethods, future events or other changes after the date of this press release,\nexcept as required by applicable law. You should not place undue reliance on\nany forward-looking statements, which are based only on information currently\navailable to Envoy Medical.\n\nInvestor Contact:\nPhil Carlson, Managing Director\nKCSA Strategic Communications\nO: 212.896.1233\nE: Envoy@kcsa.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/312455"},"type":"article","timestamp":"2026-09-02T12:30:14.849113483Z","server_sent_at_ms":1788352214849},"received_at":"2026-09-02T12:30:14.935Z","source_url":"https://www.newsfilecorp.com/release/312455"},"analysis":{"id":"122817","press_release_id":"133925","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Envoy Medical CEO Brent Lucas will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026 at 2:00 PM ET, at the Lotte New York Palace Hotel in New York City.\n\nThe presentation will be available on demand for 90 days through the company's investor relations site, and one-on-one investor meetings can be scheduled via KCSA Strategic Communications.\n\nEnvoy's story centers on fully implanted hearing devices: the investigational Acclaim cochlear implant, which received FDA Breakthrough Device Designation in 2019, and the commercially available Esteem active middle ear implant, billed as the only FDA-approved fully implanted hearing device.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance by micro-cap medtech CEO -- fold into IR calendar, no standalone post needed."},"keyFigures":{"customDimensions":{"presentation_date":"September 15, 2026","presentation_time":"2:00 PM ET","webcast_on_demand_days":90}},"namedEntities":{"people":[{"name":"Brent Lucas","role":"CEO"},{"name":"Phil Carlson","role":"Managing Director, Investor Contact at KCSA Strategic Communications"}],"products":["Esteem active middle ear implant (FI-AMEI)","Acclaim cochlear implant (Acclaim CI)"],"companies":[{"name":"Envoy Medical, Inc.","ticker":"COCH","relationship":"filer"},{"name":"H.C. Wainwright","relationship":"conference host"},{"name":"KCSA Strategic Communications","relationship":"investor relations contact"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-relations announcement that the CEO will present at the H.C. Wainwright Global Investment Conference. No new financial results, clinical data, regulatory updates, or corporate actions are disclosed."},"tickerRelevance":{"others":[],"primary":"COCH"},"globalImportance":5,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"routine-conference-announcement","sectorWeight":"medical-devices","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Envoy Medical CEO Brent Lucas will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026 at 2:00 PM ET, at the Lotte New York Palace Hotel in New York City.\n\nThe presentation will be available on demand for 90 days through the company's investor relations site, and one-on-one investor meetings can be scheduled via KCSA Strategic Communications.\n\nEnvoy's story centers on fully implanted hearing devices: the investigational Acclaim cochlear implant, which received FDA Breakthrough Device Designation in 2019, and the commercially available Esteem active middle ear implant, billed as the only FDA-approved fully implanted hearing device.","key_figures":{"customDimensions":{"presentation_date":"September 15, 2026","presentation_time":"2:00 PM ET","webcast_on_demand_days":90}},"named_entities":{"people":[{"name":"Brent Lucas","role":"CEO"},{"name":"Phil Carlson","role":"Managing Director, Investor Contact at KCSA Strategic Communications"}],"products":["Esteem active middle ear implant (FI-AMEI)","Acclaim cochlear implant (Acclaim CI)"],"companies":[{"name":"Envoy Medical, Inc.","ticker":"COCH","relationship":"filer"},{"name":"H.C. Wainwright","relationship":"conference host"},{"name":"KCSA Strategic Communications","relationship":"investor relations contact"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T15:22:26.904Z","global_importance":5,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap","eventGravity":"routine-conference-announcement","sectorWeight":"medical-devices","issuerAuthored":true}},"durationMs":179770,"modelName":"glm-4.7"}}